[go: up one dir, main page]

AU5920400A - Cell-based assay systems for examining hcv ns3 protease activity - Google Patents

Cell-based assay systems for examining hcv ns3 protease activity

Info

Publication number
AU5920400A
AU5920400A AU59204/00A AU5920400A AU5920400A AU 5920400 A AU5920400 A AU 5920400A AU 59204/00 A AU59204/00 A AU 59204/00A AU 5920400 A AU5920400 A AU 5920400A AU 5920400 A AU5920400 A AU 5920400A
Authority
AU
Australia
Prior art keywords
cell
protease activity
based assay
assay systems
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU59204/00A
Inventor
Anu Bansal
Claudio Pasquinelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU5920400A publication Critical patent/AU5920400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AU59204/00A 1999-07-07 2000-07-07 Cell-based assay systems for examining hcv ns3 protease activity Abandoned AU5920400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14256199P 1999-07-07 1999-07-07
US60142561 1999-07-07
PCT/US2000/018590 WO2001002601A2 (en) 1999-07-07 2000-07-07 Cell-based assay systems for examining hcv ns3 protease activity

Publications (1)

Publication Number Publication Date
AU5920400A true AU5920400A (en) 2001-01-22

Family

ID=22500325

Family Applications (2)

Application Number Title Priority Date Filing Date
AU57888/00A Abandoned AU5788800A (en) 1999-07-07 2000-07-07 Peptide boronic acid inhibitors of hepatitis c virus protease
AU59204/00A Abandoned AU5920400A (en) 1999-07-07 2000-07-07 Cell-based assay systems for examining hcv ns3 protease activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU57888/00A Abandoned AU5788800A (en) 1999-07-07 2000-07-07 Peptide boronic acid inhibitors of hepatitis c virus protease

Country Status (4)

Country Link
EP (1) EP1196436A2 (en)
AU (2) AU5788800A (en)
CA (1) CA2376965A1 (en)
WO (2) WO2001002601A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
WO2002048116A2 (en) * 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
WO2002054931A2 (en) * 2001-01-10 2002-07-18 Bristol Myers Squibb Company P Alpha-aminoboronic acids prepared by novel synthetic methods
CA2435124A1 (en) 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7371729B2 (en) 2002-09-09 2008-05-13 Trigen Limited Boronic acid salts useful in parenteral formulations
EP1396269A1 (en) 2002-09-09 2004-03-10 Trigen Limited Boronic acid salts of multivalent metals used in the preparation of a medicament for treating thrombosis
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
US20050090450A1 (en) * 2003-04-11 2005-04-28 Farmer Luc J. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
ES2297424T3 (en) 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh INHIBITING COMPOUNDS OF HEPATITIS C.
WO2005024051A1 (en) * 2003-06-23 2005-03-17 Vanderbilt University Cell-based assay for identifying peptidase inhibitors
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AR045596A1 (en) * 2003-09-05 2005-11-02 Vertex Pharma INHIBITORS OF SERINE PROTEASES IN PARTICULAR HCV PROTEASA NS3-NS4A
DE602004031645D1 (en) 2003-09-22 2011-04-14 Boehringer Ingelheim Pharma MACROCYCLIC PEPTIDES WITH EFFECT AGAINST HEPATITIS C VIRUS
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
ATE483708T1 (en) 2004-03-08 2010-10-15 Prosidion Ltd PYRROLOPYRIDINE-2-CARBONIC ACID HYDRAZIDES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE
TW200612967A (en) 2004-06-14 2006-05-01 Anacor Pharmaceuticals Inc Anti-viral uses of borinic acid complexes
JP4914355B2 (en) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hepatitis C inhibitor peptide analog
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
ES2324173T3 (en) 2004-12-02 2009-07-31 Prosidion Limited AMIDAS OF THE ACID PIRROLOPIRIDIN-2-CARBOXILICO.
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2006228957A1 (en) * 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
US20090325889A1 (en) * 2005-08-01 2009-12-31 David Alan Campbell Hepatitis c serine protease inhibitors and uses therefor
EP2027143A2 (en) 2006-05-23 2009-02-25 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
WO2008070733A2 (en) * 2006-12-06 2008-06-12 Phenomix Corporation Macrocyclic hepatitis c serine protease inhibitors and uses therefor
WO2008097676A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EA030685B1 (en) 2008-06-17 2018-09-28 Милленниум Фармасьютикалз, Инк. Process for the preparation of a boronate ester compound
AR075090A1 (en) 2008-09-29 2011-03-09 Millennium Pharm Inc ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
EP2516449A1 (en) 2009-12-22 2012-10-31 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
AR080185A1 (en) * 2010-02-19 2012-03-21 Glaxo Group Ltd DERIVATIVES OF BORONIC AND BENZOFURAN ACID, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE OF THE SAME IN THE TREATMENT AND / OR PREVENTION OF VIRAL INFECTIONS, IN PARTICULAR BY HEPATITIS C (HCV) VIRUSES.
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
WO2012067663A1 (en) * 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US9119868B2 (en) * 2011-08-17 2015-09-01 Glaxosmithkline Llc Therapeutic methods
EP3199531A1 (en) * 2011-08-19 2017-08-02 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
UY36132A (en) 2014-05-20 2015-11-30 Millennium Pharm Inc METHODS FOR CANCER THERAPY
CN107074885B (en) * 2014-10-01 2020-11-27 默克专利股份公司 Boronic acid derivatives
SG11201702623TA (en) 2014-10-01 2017-04-27 Merck Patent Gmbh Boronic acid derivatives
US10669289B2 (en) * 2014-10-01 2020-06-02 Merck Patent Gmbh Boronic acid derivatives
DK3472149T3 (en) 2016-06-21 2023-11-27 Orion Ophthalmology LLC HETEROCYCLIC PROLINE MID DERIVATIVES
JP7164521B2 (en) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー carbocyclic prolinamide derivatives
CA3179181A1 (en) 2021-03-15 2022-09-22 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599906A (en) * 1990-04-13 1997-02-04 Schering Corporation Protease assays
IT1272179B (en) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV.
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
KR100209095B1 (en) * 1996-06-28 1999-07-15 성재갑 Substitution hepatitis c virus which can be used for detecting the activity of the hcv protease, and recombinant gene and use
UA66767C2 (en) * 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Serine proteases inhibitors, pharmaceutical composition, a method for inhibitining activity and a method for treatment or prevention of viral infection of hepatitis c
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998037180A2 (en) * 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
IL134232A0 (en) * 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
US6280940B1 (en) * 1998-08-05 2001-08-28 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
MXPA01011045A (en) * 1999-05-04 2002-07-22 Boehringer Ingelheim Ltd Surrogate cell-based system and method for assaying the activity of hepatitis c virus ns3 protease.

Also Published As

Publication number Publication date
WO2001002601A2 (en) 2001-01-11
WO2001002424A2 (en) 2001-01-11
EP1196436A2 (en) 2002-04-17
CA2376965A1 (en) 2001-01-11
AU5788800A (en) 2001-01-22
WO2001002424A3 (en) 2001-07-19
WO2001002601A3 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
AU5920400A (en) Cell-based assay systems for examining hcv ns3 protease activity
AU7063598A (en) Hepatitis c ns3 protease inhibitors
AUPR005600A0 (en) Diagnostic assay
AU3440900A (en) Assay system
AU2001253206A1 (en) Ns5b hcv polymerase inhibitors
AUPP312998A0 (en) Diagnostic assay
AU2001262906A1 (en) Peptide biosensors for anthrax protease
AU5459000A (en) Highly sensitive biological agent probe
AU3465399A (en) Diagnostic modified-nucleoside detection assay
AU6800100A (en) Alpha regions
AU3902099A (en) Tethered function assay for protein function
HUP0200945A3 (en) Surrogate cell-based system and method for assaying the activity of hapatitis c virus ns3 protease
AU5179400A (en) Switching complex architecture and operation
IL125187A0 (en) Rapid microbial protease assay
AU2016100A (en) New assay
AU2002221966A1 (en) Enzyme with proteolytic activity
AU4586700A (en) Improved assay and reagents therefor
AU2001241714A1 (en) Micro-label biological assay system
AU5763100A (en) Non-destructive cell-based assay
AU7537400A (en) Assay
AU7618400A (en) Human ubiquitin protease
AU2533299A (en) Microbial assay
AU2813800A (en) High throughput assay
AU2813700A (en) Protein assay
GB9910499D0 (en) Assay reagent

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase